420 with CNW — Trial on Marijuana Drug Effectiveness in Brain Cancer Treatment Receives Clearance

December 6, 2021 16:25:26

The Brain Tumor Charity recently announced that it had received clearance to conduct a trial to evaluate the effectiveness of a marijuana-based drug in the treatment of recurrent glioblastoma. The general public supported a campaign to raise £400,000 ($532,000) for the charity, which would finance the three-year trial.

The research, which will be led by a University of Leeds expert, will examine whether incorporating the use of an oral spray called Sativex, which contains cannabinoids, in chemotherapy could prolong life for individuals who have been diagnosed with recurrent glioblastoma. This is in addition to evaluating whether the addition of the cannabinoid spray to chemotherapy will improve patient quality of life and/or delay the disease’s progression.

The average rate of survival after diagnosis for this aggressive type of brain cancer, even after patients undergo intensive treatment, is 12 to 18 months. Research has shown that this aggressive form of cancer is common, with figures showing that more than 2,000 individuals are diagnosed with this form of brain cancer annually in England.

The rate of growth of glioblastomas is also high in comparison to other cancers, with researchers finding that for untreated glioblastomas, the rate was 1.4% per day.

The trial plans to recruit 230 patients from 15 hospitals across the United Kingdom early in 2022. University of Leeds Professor Susan Short, who is the principal investigator on the study, stated that the treatment of glioblastomas was challenging. Short, who has majored in neuro-oncology and clinical oncology, explained that even with chemotherapy, radiotherapy and surgery, almost all of these brain tumors regrew in a year, noting that this meant that patients were left with few options.

Short highlighted the growing interest in cannabinoids and their use in various cancers, adding that these compounds had well-described effects in the brain. In addition, Short explained that research had shown that glioblastoma brain tumors had receptors to cannabinoids on their cell surface, citing lab studies which had demonstrated that cannabinoid-based drugs worked well when added to temozolomide chemotherapy and could slow tumor growth. The researchers added that they were excited to add to these previous findings and evaluate whether the drug could extend the lives of glioblastoma patients.

Brain Tumor Charity’s interim chief executive Dr. David Jenkinson asserted that researchers were excited to conduct this world-first trial in the United Kingdom. In addition to having Olympic champion Tom Daley back the trial, Leeds Hospital Charity donated £45,000 ($60,000) to the campaign.

This trial could add further credence to the existence of medicinal cannabis products manufactured by companies such as Simply Sonoma Inc.

NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma Inc. are available in the company’s newsroom at https://cnw.fm/Sonoma

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

Denver, Colorado
303.498.7722 Office

CNW420 is part of the InvestorBrandNetwork.